Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FDJB4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,642
Award facts
- Contract value 100% obligated
- $14,642.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $14,642.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on October 22, 2025, with an ultimate completion date of October 23, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy designed to provide pharmaceutical and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, serves as a critical pharmaceutical supplier within the federal military medical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support DoD healthcare operations globally. The company's IDC under the PPV-G GEN V program, awarded on November 13, 2025, with a ceiling value of $499.999 billion and completion date of December 31, 2036, positions it as one of multiple regional prime vendor contractors authorized to fulfill diverse and specialized pharmaceutical requirements for the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FDJB4?
SPE2DR26FDJB4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DR26FDJB4 worth?
The government has obligated $14,642 on SPE2DR26FDJB4.
Is contract SPE2DR26FDJB4 an order under another contract?
Yes. SPE2DR26FDJB4 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJB4 competed?
The extent of competition for SPE2DR26FDJB4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award